Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SALVO: Adjuvant Ipilimumab and Nivolumab for Resected Mucosal Melanoma
NCT03241186Phase 2Active, not recruiting
- Start
- Sep 2017
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of ipilimumab and nivolumab in mucosal melanoma (MM). Started Sep 2017; status: active, not recruiting.
02
Drugs
ipilimumabnivolumab
03
Conditions
mucosal melanoma (MM)
Beyond the preview
Go deeper on NCT03241186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03241186.